Operational Information Sharing
Guidance for Marketing Authorisation (MA) applicants on providing consent to share operational information during the MA application process.
Latest change: Last updated 2 January 2026 - Amended the Operational Information Sharing Guidance to reflect the addition of Department of Health Northern Ireland to the list of Health System Partners. JM
AI Summary
The Medicines and Healthcare products Regulatory Agency (MHRA), an executive agency of the UK Department of Health and Social Care (DHSC), has introduced a guidance document regarding the sharing of operational information with health system partners. This initiative aims to accelerate patient access to new treatments by facilitating communication between regulators and healthcare providers. The regulatory framework applies to Marketing Authorisation Applications (MAAs) for new active substances or variations for extensions of indication, specifically those submitted through National and International Recognition pathways. The guidance details the nature of the information to be shared and the protocols for data management. For pharmaceutical companies and applicants, the primary required action is to manage the consent process during the MAA submission via the Human Medicines Portal. The document outlines how applicants can grant or withdraw consent for their operational data to be shared with partners across the UK health system. While this document is a procedural guidance rather than an inspection report—and thus contains no specific company violations or inspection dates—it establishes a formalised process for information exchange to support the timely availability of medicines. By participating in this voluntary sharing process, applicants enable health system partners to prepare for the introduction of new therapies more effectively.
The full document, source attachments, and change history are available on KeyPedia. Sign in to view.